Christopher L. Moertel, MD, serves as medical director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs and professor of pediatric hematology and oncology at the University of Minnesota.
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.